**1. Financial Highlights:** Vimta Labs reported strong Q1 FY26 results with Total Income of ₹99.3 Cr, up 31.4% YoY.

Profit After Tax (PAT) surged 36.0% YoY to ₹18.9 Cr, while EBITDA grew 33.1% YoY to ₹35.4 Cr, maintaining a healthy 35.7% margin.

Capex for the quarter stood at ₹24.1 Cr.

The balance sheet shows low debt of ₹7.0 Cr against ₹15.0 Cr cash. **2. Strategic Initiatives & Growth Drivers:** The company is focused on capacity expansions, service innovations, and new market penetration.

Key growth drivers include rising demand for safe drugs, food, and clean environment, alongside a commitment to operational excellence, talent acquisition, cutting-edge technologies, and strong corporate governance. **3. Business Developments:** Vimta Labs operates across four key service areas: drug discovery & development, food & agri testing, electronics & electricals testing, and environment testing & consultancy.

With over 41 years of experience, it boasts 600,000+ sq ft of lab space and a team of 1,300+ professionals across 10 locations. **4. Market Position & Competitive Advantage:** Vimta Labs holds a #1 position in India for Pharma Analytical and Food Testing, and is a leading provider for EMI/EMC testing.

The company attributes its strong market standing to unparalleled infrastructure, robust compliance, continuous innovation, deep knowledge, and customer-centric long-term partnerships. **5. Investor Implications:** These results and strategic focus indicate positive growth potential for Vimta Labs.

Strong Q1 performance, market leadership in critical segments, and a focus on expanding capabilities in high-demand areas suggest continued business expansion and value creation.